CGP 53716: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9864718 |
| CHEMBL ID | 20926 |
| SCHEMBL ID | 9782 |
| MeSH ID | M0245312 |
| Synonym |
|---|
| n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| n-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide |
| bdbm50240407 |
| n-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)benzamide |
| CHEMBL20926 , |
| SCHEMBL9782 |
| cgp-53716 |
| cgp53716 |
| n-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide |
| AKOS032953616 |
| n-(4-methyl-3(4-(pyridine-3-yl)pyrimidin-2-ylamino)phenyl)benzamide |
| mfcd00945675 |
| 152459-94-4 |
| BS-15548 |
| cgp53716;cgp 53716 |
| VCC347042 |
| BCP34642 |
| benzamide, n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- |
| C72889 |
| A921531 |
| CGA45994 |
| cgp 53716 |
| CS-0021956 |
| HY-101837 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "CGP 53716 did not inhibit the number of replicating bromodeoxyuridine (BrdU)-incorporating cells in the intima, media, or adventitia during BrdU labeling at 0-96 postoperative h, though it inhibited significantly (P<0.01) the replication of medial and intimal cells from 93 h onward." | ( Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. Buchdunger, E; Calderon, L; Häyry, P; Lemström, K; Myllärniemi, M, 1997) | 1.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with CGP 53716, a protein-tyrosine kinase inhibitor selective for PDGF receptor, alone and in combination with suboptimal doses of cyclosporin A, significantly reduced myofibroproliferation and the degree of OB by more than 50%." | ( Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Aavik, E; Buchdunger, E; Kallio, EA; Koskinen, PK; Lemström, KB, 1999) | 0.64 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 6.5491 | 0.0001 | 0.7128 | 10.0000 | AID632955; AID743664 |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | IC50 (µMol) | 0.1000 | 0.0018 | 0.7552 | 9.5000 | AID371451 |
| Breakpoint cluster region protein | Homo sapiens (human) | IC50 (µMol) | 0.3981 | 0.0003 | 0.6200 | 10.0000 | AID743664 |
| Platelet-derived growth factor receptor alpha | Mus musculus (house mouse) | IC50 (µMol) | 0.1000 | 0.0018 | 0.8572 | 9.5000 | AID371451 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID632955 | Inhibition of Abl using DAIpYAAPFAKKK phosphopeptide as substrate by MALDI-MS analysis | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. |
| AID743664 | Inhibition of BCR-ABL kinase (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8 | BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. |
| AID632954 | Inhibition of Abl at 10 uM using DAIpYAAPFAKKK phosphopeptide as substrate by MALDI-MS analysis | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. |
| AID371451 | Inhibition of PDGFR autophosphorylation in mouse Swiss 3T3 fibroblast by immunoblotting | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||